oncbrain — oncology meeting digest

ES-SCLC Concurrent TRT + Chemoimmunotherapy (LBA8005)

Tue, 02 Jun 2026 00:00:00 GMT

[Confirmatory] mOS 10.0 vs 11.8mo, HR 1.14, p=0.40: concurrent TRT adds no OS benefit to chemoIO in ES-SCLC. Eligible: ES-SCLC, treatment-naïve, ECOG 0-1, measurable thoracic lesion

DeLLphi-304 (tarlatamab CNS outcomes)

Mon, 01 Jun 2026 00:00:00 GMT

[Caveats dominate] CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC. Eligible: 2L ES-SCLC; brain mets subgroup ≥1 BM at baseline, >70% prior CNS treatment

RASolute 302

Sun, 31 May 2026 00:00:00 GMT

[Practice-changing] Daraxonrasib vs IC chemo in 2L RAS G12 mPDAC: mOS 13.2 vs 6.6 mo, HR 0.40 (0.30-0.54), p<0.001. Eligible: Prev-treated metastatic PDAC, RAS G12 mutation, ≥1 prior systemic line

A-DREAM (ALLIANCE mAPMS)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] ADT+ARPI interruption in mHSPC: 41% treatment-free with eugonadal T at 18mo (1° EP); 38.5% still off-tx at 26.9mo FU. Eligible: mHSPC achieving PSA<0.2 after ≥18-24mo ADT+ARPI, low-volume predominant

ENZAMET + Decipher Biomarker Analysis

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] Decipher >0.85 identifies mHSPC pts with OS benefit from docetaxel intensification; IPTW interaction p=0.04, HR 0.75 (0.43-1.33). Eligible: mHSPC, ADT + enzalutamide backbone, tumor tissue available for Decipher testing

TALAPRO-3

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] 3yr rPFS 77% vs 56% (HR 0.48, p<0.001) favoring talazoparib+enza+ADT in HRR-deficient mHSPC. Eligible: HRR-deficient metastatic hormone-sensitive prostate cancer

CHRYSALIS-2 (1L Ami+Laz, Atypical EGFR+)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Median OS 41.0 mo (95% CI 27.7-NE) with ami+laz in 1L atypical EGFR+ advanced NSCLC; single-arm, n=49. Eligible: Advanced NSCLC, atypical EGFR mutation, treatment-naive

ESAONA

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Intracranial ORR 95.5% vs 79.6% (p=0.0004), iPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR+ NSCLC with brain mets. Eligible: 1L EGFR-mutated NSCLC with active brain metastases

OptiTROP-Lung05

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] mPFS NR vs 5.7mo, HR 0.35 (0.26-0.47), p<0.0001 favoring sac-TMT + pembro in 1L PD-L1+ NSCLC. Eligible: Stage IIIB-IV NSCLC, PD-L1 TPS ≥1%, no EGFR/ALK, treatment-naive, ECOG 0-1

Wait or Treat — NCT05236946 (Upfront vs Delayed Brain RT in Oncogene-mutated NSCLC)

Fri, 29 May 2026 00:00:00 GMT

[Challenges SOC] Upfront brain RT halves icPD (HR 0.35, p<0.001) but OS numerically favors delayed (HR 1.45, 2yr 60% vs 48%) in EGFR/ALK+ mNSCLC. Eligible: Metastatic NSCLC, EGFR or ALK mutant, completely asymptomatic BM, ECOG 0-2

OLIGOMA

Sun, 17 May 2026 00:00:00 GMT

[Early signal] mPFS 35.8 vs 20.4 mo, HR 0.48; first RCT positive for MDT in oligometastatic breast cancer. Eligible: Metastatic breast, ≤5 mets, any systemic therapy line